medigraphic.com
ISSN 1025-0298 (Electronic)
ISSN 1025-028X (Print)

2021, Number 2

<< Back

VacciMonitor 2021; 30 (2)

Adoption of Euvax-B vaccine in Nineveh

Dawood AA, Altobje MA, Al-Rrassam ZT

Language: English
References: 25
Page: 91-95
PDF size: 345.53 Kb.


ABSTRACT

Hepatitis B infection is one of the most important health problems around the world. The high mortality rate of the hepatitis B encouraged research that led to the finding of an effective vaccine against it. The aim of the present study was to find out the use of the Euvax-B vaccine in sectors of Nineveh province. According to the results obtained in this study, in the next five years, the vaccination coverage for the second and third doses needs to improve.


REFERENCES

  1. Wiesen E, Diorditsa S, Li X. Progress towards hepatitis B prevention through vaccination in the Western Pacific, 1990-2014. Vaccine. 2016;34:2855-62.doi:https://10.1016/j.vaccine.2016.03.060.

  2. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet.2015;386:1546-55. doi: https://10.1016/S0140-6736(15)61412-X.

  3. Han S. Clinical vaccine development. Clin Exp Vaccine Res 2015; 4:46-53. doi: https://10.7774/cevr.2015.4.1.46.

  4. Bian T, Yan H, Shen L, Wang F, Zhang S, Cao Y, et al. Change in hepatitis B virus large surface antigen variant prevalence 13 years after implementation of a universal vaccination program in China. J Virol. 2013;87:12196-206. doi:https://10.1128/JVI.02127-13.

  5. Lian ZL, Tian QN, Liu Y, Cento V, Salpini R, Perno CF, et al. Detecting Hepatitis B Viral Amino Acid Sequence Mutations in Occult Hepatitis B Infections via Bayesian Partition Model. J Proteomics Bioinform. 2013; S6-005. doi:https://10.4172/jpb.S6-005.

  6. Cha SH. The history of vaccination and current vaccination policies in Korea. Clin Exp Vaccine Res 2012;1:3-8.

  7. Lok AS, Pan CQ, Han SH, Trinh HN, Fessel WJ, Rodell T,et al. Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J Hepatol. 2016;65:509-16. doi:https://10.1016/j.jhep.2016.05.016.

  8. Yang S, Tian G, Cui Y, Ding C, Deng M, Yu C, et al. Factors influencing immunologic response to hepatitis B vaccine in adults. Sci Rep 2016;6:27251. doi: https:// 10.1038/srep27251.

  9. Lin AW, Wong KH. Long-term protection of neonatal hepatitis B vaccination in a 30-year cohort in Hong Kong. J Hepatol 2013;59:1363-4. doi:https://10.1016/j.jhep.2013.08.021.

  10. Sandhu P, Haque M, Humphries-Bickley T, Ravi S, Song J. Hepatitis B virus immunopathology, model systems, and current therapies. Front Immunol. 2017; 8:436. doi: https://10.3389/fimmu.2017.00436.

  11. Lee LY, Chan SM, Ong C, M Aw M, Wong F, Saw S, et al. Comparing monovalent and combination hepatitis B vaccine outcomes in children delivered by mothers with chronic hepatitis B. J Paediatr Child Health. 2019;55:327-32. doi: https://10.1111/jpc.14194.

  12. Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward JW, et al. Prevention of hepatitis B virus infection in the United States: Recommendations of the advisory committee on immunization practices. MMWR Recomm Rep. 2018; 67:1-31. doi: https://10.15585/mmwr.rr6701a1.

  13. Chen X, Tang Y, Zhang Y, Zhuo M, Tang Z, Yu Y, et al. Tapasin modification on the intracellular epitope HBcAg18-27 enhances HBV-specific CTL immune response and inhibits hepatitis B virus replication in vivo. Lab Invest. 2014;94:478-90. doi: https://10.1038/labinvest.2014.6.

  14. Chen TW. Paths toward hepatitis B immunization in South Korea and Taiwan. Clin Exp Vacc Res. 2013; 2:76-82. doi: https://10.7774/cevr.2013.2.2.76.

  15. World Health Organization. Hepatitis B vaccines: WHO position paper, July 2017 - Recommendations. Vaccine. 2019; 37:223-5. doi: https://10.1016/j.vaccine.2017.07.046.

  16. Shimakawa Y, Lemoine M, Njai HF, Bottomley C, Ndow G, Goldin RD, et al. Natural history of chronic HBV infection in West Africa: a longitudinal population based study from The Gambia. Gut. 2016; 65: 2007-16. doi: https://10.1136/gutjnl-2015-309892.

  17. Shouval D, Roggendorf H, Roggendorf M. Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine. Med Microbiol Immunol. 2015; 204:57-68. doi: https://10.1007/s00430-014-0374-x.

  18. Gong J, Liu X. Effect of HBIG combined with hepatitis B vaccine on blocking HBV transmission between mother and infant and its effect on immune cells. Exp Ther Med. 2018;15:919-23. doi: https://10.3892/etm.2017.5474.

  19. Sticchi L, Caligiuri P, Cacciani R, Alicino C, Bruzzone B. Epidemiology of HBV S-gene mutants in the Liguria Region, Italy: Implications for surveillance and detection of new escape variants. Hum Vaccin Immunother. 2013;9:568-71. doi: https://10.4161/hv.23236.

  20. Meireles LC, Marinho RT, Van Damme P. Three decades of hepatitis B control with vaccination. World J Hepatol. 2015;7:2127-32. doi: https://10.4254/wjh.v7.i18.2127.

  21. Dawood A, and Altobje M. Correlation between CXCL-motif-10 and IFN- ? on Hemodialysis Patients with HCV under Treatment. Int J Eme Tech. 2019; 10(3): 208-215.

  22. Leroux-Roels G. Old and new adjuvants for hepatitis B vaccines. Med Microbiol Immunol. 2015; 204:69-78. doi: https://10.1007/s00430-014-0375-9.

  23. Ninawa PHI. Yearly Report for Transport Diseases and Vaccination in Nineveh. 2018, Mosul: DPHS;2018.

  24. Dawood A, Hasan G, Hayawi A. Determination Genotype D of Hepatitis B Virus amongst Patients in Mosul-Iraq. Int J Sci & Tech Res. 2019; 8(9): 1218-1220.

  25. Tajiri K, Shimizu Y. Unsolved problems and future perspectives of hepatitis B virus vaccination. World J Gastroenterol. 2015; 21:7074-83. doi: https://10.3748/wjg.v21.i23.7074.




2020     |     www.medigraphic.com